Table 1.
iNKT cell based immunotherapy.
| Cancer type | Number of patients (completed/enrolled) | Phase | Treatment (injection) | Number of cells injected | Number of injection | Immunological responses | Clinical outcomes | References |
|---|---|---|---|---|---|---|---|---|
| NSCLC | 9/11 | I | α-GalCer-pulsed APCs | Level 1: 5 × 107 cells/m2 Level 2: 2.5 × 108 cells/m2 Level 3: 1 × 109 cells/m2 |
4 |
 iNKT cell number 3/3 patients (level 3) |
(10) | |
| 17/23 | I-II | α-GalCer-pulsed APCs | 1 × 109 cells/m2 |
4 |
iNKT cell number 6/17 patients IFN-γ producing cell number 10/17 patients |
(11) | ||
| 4/4 | (–) | α-GalCer-pulsed APCs | 1 × 109 cells/m2 |
1 |
% of iNKT cells in TILs |
(12) | ||
| 6/6 | I | iNKT cells | Level 1: 1 × 107 cells/m2 Level 2: 5 × 107 cells/m2 |
2 |
iNKT cell number 2/3 patients (level 2) IFN-γ producing cell number 3/3 patients (level 2) |
(13) | ||
| HNC | 9/9 | I | α-GalCer-pulsed APCs | 1 × 108 cells/m2 |
2 |
iNKT cell number 4/9 patients IFN-γ producing cell number 8/9 patients |
PR 1/9 SD 5/9 PD 3/9 |
(14) |
| 8/8 | I | α-GalCer-pulsed APCs iNKT cells | 1 × 108 cells/m2 5 × 107 cells/m2 |
2 1 |
iNKT cell number 7/8 patients IFN-γ producing cell number 7/8 patients |
PR 3/8 SD 4/8 PD 1/8 |
(15) | |
| 10/10 | II | α-GalCer-pulsed APCs iNKT cells | 1 × 108 cells/m2 5 × 107 cells/m2 |
1 1 |
iNKT cell number 9/10 patients IFN-γ producing cell number 10/10 patients |
PR 5/10 SD 5/10 |
(16) |